Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Advanced / Recurrent Endometrial Carcinoma — Systemic Therapy

First-line Second-line SECOND-LINE Advanced / recurrent endometrial carcinoma 1L — dMMR / MSI-high 1L — MMR-proficient Later-line Chemo+IO Carbo/paclitaxel + dostarlimab RUBY ↗ Chemo+IO Carbo/paclitaxel + pembrolizumab NRG-GY018 ↗ Chemo+IO Carbo/paclitaxel + immunotherapy RUBY / NRG-GY018 ↗ pMMR Pembrolizumab + lenvatinib KEYNOTE-775 ↗ dMMR Single-agent checkpoint GARNET ↗ HER2+ serous Trastuzumab-based HER2-directed